Literature DB >> 7504475

O-antigenic lipopolysaccharide of Vibrio cholerae O139 Bengal, a new epidemic strain for recent cholera in the Indian subcontinent.

K Hisatsune1, S Kondo, Y Isshiki, T Iguchi, Y Kawamata, T Shimada.   

Abstract

Lipopolysaccharide (LPS) from Vibrio cholerae O139 Bengal contained colitose (3,6-dideoxy-L-galactose) in addition to glucose, L-glycero-D-manno-heptose, fructose, glucosamine and quinovosamine in its polysaccharide and only glucosamine in lipid A, while perosamine, a characteristic component sugar of V. cholerae O1 LPS, was absent. 3-Hydroxydodecanoic, tetradecanoic and hexadecanoic acids as ester-bound fatty acids and 3-hydroxytetradecanoic acid as amide-bound fatty acid were identified in the lipid A. A very high serological specificity of O139 LPS distinct from that of O1 V. cholerae was demonstrated by passive hemolysis and passive hemolysis inhibition tests by using the LPS either as antigen for sensitizing sheep red blood cells or as inhibitor in the latter test.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504475     DOI: 10.1006/bbrc.1993.2395

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  The structure of GDP-4-keto-6-deoxy-D-mannose-3-dehydratase: a unique coenzyme B6-dependent enzyme.

Authors:  Paul D Cook; James B Thoden; Hazel M Holden
Journal:  Protein Sci       Date:  2006-09       Impact factor: 6.725

2.  Isolation and characterization of rugose form of Vibrio cholerae O139 strain MO10.

Authors:  Y Mizunoe; S N Wai; A Takade; S I Yoshida
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

3.  Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.

Authors:  Anne L Bishop; Stefan Schild; Bharathi Patimalla; Brian Klein; Andrew Camilli
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

4.  Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera.

Authors:  F Qadri; F Ahmed; M M Karim; C Wenneras; Y A Begum; M Abdus Salam; M J Albert; J R McGhee
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 5.  Vibrio cholerae O139 Bengal.

Authors:  M J Albert
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

6.  Distribution and virulence of Vibrio cholerae belonging to serogroups other than O1 and O139: a nationwide survey.

Authors:  A K Mukhopadhyay; P K Saha; S Garg; S K Bhattacharya; T Shimada; T Takeda; Y Takeda; G B Nair
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

7.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

8.  The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.

Authors:  M K Waldor; R Colwell; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

9.  Two site-directed mutations are required for the conversion of a sugar dehydratase into an aminotransferase.

Authors:  Paul D Cook; Rachel L Kubiak; Daniel P Toomey; Hazel M Holden
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

10.  Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.

Authors:  F Qadri; G Mohi; J Hossain; T Azim; A M Khan; M A Salam; R B Sack; M J Albert; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.